<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Emmett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 29, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a disorder of impaired water excretion caused by the inability to suppress the secretion of antidiuretic hormone (ADH) [<a href="#rid1">1</a>]. If water intake exceeds the reduced urine output, the ensuing water retention leads to the development of hyponatremia.</p><p>The SIADH should be suspected in any patient with hyponatremia, hypoosmolality, and a urine osmolality above 100 mosmol/kg. In SIADH, the urine sodium concentration is usually above 40 mEq/L, the serum potassium concentration is normal, there is no acid-base disturbance, and the serum uric acid concentration is frequently low [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/2354.html" rel="external">"Diagnostic evaluation of adults with hyponatremia"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120063">(Related Pathway(s):  <a class="utd-content-120063" href="/pathway/120063?topicRef=2384&amp;source=see_link">Hyponatremia: Evaluation in adults</a>.)</span></p><p>The pathophysiology and etiology of SIADH will be reviewed here. The treatment of this disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Pathogenesis of hyponatremia</span><span class="headingEndMark"> — </span>The plasma sodium concentration (PNa) is a function of the ratio of the body's content of exchangeable sodium and potassium (Na<sub>E</sub> and K<sub>E</sub>) and total body water (TBW) as described by Edelman's classic equation:</p><div class="formulaContainer"><div class="formula"><p>  PNa  ≈  (Na<sub>E</sub> + K<sub>E</sub>)/Total body water</p></div></div><p>Antidiuretic hormone (ADH, arginine vasopressin) secretion results in a concentrated urine and therefore a reduced urine volume. The higher the plasma ADH, the more concentrated the urine. In most patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), ingestion of water does not adequately suppress ADH, and the urine remains concentrated. This leads to water retention, which increases TBW. This increase in TBW lowers the plasma sodium concentration by dilution (see above equation) [<a href="#rid1">1</a>]. In addition, the increase in TBW transiently expands the extracellular fluid volume and thereby triggers increased urinary sodium excretion, which both returns the extracellular fluid volume toward normal and further lowers the plasma sodium concentration.</p><p>Hyponatremia can occur in SIADH even if the only fluid given is isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> [<a href="#rid2">2</a>]. The mechanism by which this occurs and why isotonic saline administration can lower the plasma sodium concentration in patients with SIADH and a highly concentrated urine is discussed separately. (See  <a class="medical medical_review" href="/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat", section on 'Intravenous hypertonic saline'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Patterns of ADH secretion</span><span class="headingEndMark"> — </span>In normal individuals, plasma ADH levels are very low when the plasma osmolality is below 280 mosmol /kg, thereby permitting the excretion of ingested water, and ADH levels increase progressively as the plasma osmolality rises above 280 mosmol/kg (<a class="graphic graphic_figure graphicRef65195" href="/d/graphic/65195.html" rel="external">figure 1</a>).</p><p>ADH regulation is impaired in SIADH; five different patterns have been described [<a href="#rid3">3-5</a>]. The prevalence of these patterns differs among series:</p><p class="bulletIndent1"><span class="glyph">●</span>Type A is characterized by grossly elevated levels of ADH unresponsive to osmotic deviations [<a href="#rid5">5</a>]. Plasma ADH levels are often above that required for maximum antidiuresis, so the urine osmolality is typically very high. High hormone levels above the physiologic range suggest ectopic secretion of ADH, most commonly by bronchogenic carcinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type B is characterized by an abnormally low osmotic threshold for ADH release (ie, a threshold that is below the level of plasma osmolality at which plasma ADH becomes detectable in normal individuals) and a linear increase in plasma ADH in response to a rising plasma osmolality. Such patients have been described as having a "reset osmostat." Establishing the presence of this condition is important because, unlike other forms of SIADH, there is no need to be concerned that the plasma sodium will continue to fall without therapy, because ADH secretion is suppressed when the plasma osmolality falls below the reset threshold level. This disorder is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat", section on 'Reset osmostat'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type C is characterized by ADH levels that are persistently in the physiologic range and are neither suppressed by a low plasma osmolality nor stimulated by a rising plasma osmolality. This pattern differs quantitatively from type A, in which superphysiologic levels of ADH are observed. However, like type A, it could occur in patients with ectopic ADH secretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type D is characterized by normal osmoregulation (ie, ADH secretion varies appropriately with the plasma osmolality), but the urine is concentrated even if ADH release is suppressed. At least one mechanism by which this occurs is a germ cell mutation in which the vasopressin-2 (V2) receptor is constituently activated [<a href="#rid3">3</a>]. However, one study found that none of the six patients with a type D pattern had an activating mutation of the V2 receptor [<a href="#rid5">5</a>]. Other potential mechanisms include production of an antidiuretic compound other than immunoreactive arginine vasopressin and a postreceptor defect in trafficking of aquaporin-2 water channels, which mediate ADH-induced antidiuresis. (See <a class="local">'Hereditary SIADH'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type E is characterized by a decline in plasma ADH as the serum sodium concentration increases during infusion of hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. This pattern is hypothesized to be caused by altered baroreceptor signaling despite normovolemia so that a minor decrease in blood pressure or blood volume results in a large increase in ADH secretion. Similarly, a minor increase in blood pressure or blood volume caused by saline infusion results in a large decrease in ADH secretion [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Determinants of urine output</span><span class="headingEndMark"> — </span>In addition to the persistent secretion of ADH, there are two other potentially important determinants of the urine output in patients with SIADH: the rate of solute excretion and partial escape from the effect of ADH.</p><p class="headingAnchor" id="H6"><span class="h3">Solute excretion</span><span class="headingEndMark"> — </span>In normal subjects, the urine output is primarily determined by water intake. Changes in water intake lead to alterations in the plasma osmolality that are sensed by the osmoreceptors in the hypothalamus that regulate both ADH release and thirst. As an example, an increase in water intake sequentially lowers the plasma osmolality, decreases ADH secretion, and reduces collecting tubule permeability to water; the net effect is the rapid excretion of the excess water in a dilute urine.</p><p>In SIADH, however, an increase in water intake does not produce an increase in water excretion because ADH release is relatively fixed. Suppose that a patient has moderately severe SIADH with a urine osmolality that cannot be reduced below 750 mosmol/kg (the normal minimum urine osmolality is 40 to 100 mosmol/kg). In this patient, the urine output is determined by the rate of excretion of solutes (primarily sodium and potassium salts and urea). Now suppose this patient consumes a typical Western diet containing approximately 750 mosmol of solute, all of which are excreted in the urine each day. With a fixed urine osmolarity of 750 mosmol/kg, the daily urine output will be only one liter (750 ÷ 750 = 1), and it will not increase in response to increased water intake.</p><p>One way to increase water excretion in this hypothetical patient with SIADH is to prescribe a high-salt and -protein diet while restricting water ingestion. If, for example, the solute intake and therefore solute excretion rose to 1200 mosmol/day, the urine output would increase to 1.6 L/day (1200 ÷ 750 = 1.6). The increase in water excretion would then tend to raise the plasma sodium concentration toward normal.</p><p>Similar considerations concerning the role of solute intake apply when ADH effect is relatively fixed at a low level in central or nephrogenic diabetes insipidus. (See  <a class="medical medical_review" href="/d/html/2372.html" rel="external">"Urine output in arginine vasopressin disorders (diabetes insipidus)"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Escape from the effect of ADH</span><span class="headingEndMark"> — </span>Studies in experimental animals given ADH and water have shown an initial phase of water retention and hyponatremia followed by partial escape from the antidiuresis so that, despite persistently high levels of ADH, urine osmolality decreases. When the urine osmolality falls, water excretion increases, matching water intake, and the plasma sodium concentration tends to stabilize [<a href="#rid6">6,7</a>]. A similar response appears to occur in humans [<a href="#rid8">8,9</a>].</p><p>This escape from ADH-induced antidiuresis appears to be mediated by decreased expression of aquaporin-2, the ADH-sensitive water channel in the collecting tubules [<a href="#rid10">10</a>]. The regulation of aquaporin-2 in this setting appears to be unrelated to plasma or tissue osmolality [<a href="#rid11">11,12</a>].</p><p class="headingAnchor" id="H8"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>One of the following causes of persistent antidiuretic hormone (ADH) release is likely to be present in patients who fulfill the clinical criteria for the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) [<a href="#rid1">1,13</a>].</p><p class="headingAnchor" id="H9"><span class="h2">CNS disturbances</span><span class="headingEndMark"> — </span>Any CNS disorder, including stroke, hemorrhage, infection, trauma, and psychosis, can enhance ADH release. A discussion of the disturbances in water balance that may occur in patients with mental illness and a brief review of the antidiuretic action of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, a drug that can cause an SIADH picture, are found elsewhere. (See  <a class="medical medical_review" href="/d/html/2374.html" rel="external">"Causes of hypotonic hyponatremia in adults"</a>.)</p><p>As in other causes of SIADH, hyponatremia associated with intracranial bleeding, as well as other severe neurologic events, is due to ADH-mediated water retention and to urinary sodium losses. However, with these severe neurologic conditions, there is uncertainty as to whether the sodium losses are a result of SIADH-induced expansion of the extracellular volume or whether they are caused by salt wasting (ie, cerebral salt wasting), with release of ADH that is secondary to a reduction in extracellular fluid volume. (See <a class="local">'Cerebral salt wasting'</a> below.)</p><p>Because of this uncertainty, therapy of hyponatremia in patients with CNS disorders usually requires the administration of hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, rather than fluid restriction or isotonic saline. (See <a class="local">'Cerebral salt wasting'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Malignancies</span><span class="headingEndMark"> — </span>Ectopic production of ADH by a tumor is most often due to a small cell carcinoma of the lung and is rarely seen with other lung tumors [<a href="#rid1">1,14</a>]. Less common causes of malignancy-associated SIADH include head and neck cancer, olfactory neuroblastoma (esthesioneuroblastoma), and extrapulmonary small cell carcinomas [<a href="#rid15">15-17</a>].</p><p>Ectopic ADH secretion by tumor cells has been documented in vitro. In addition, some small cell lung cancer cells increase ADH secretion in response to high osmolality, suggesting a degree of regulation of the ectopic secretion [<a href="#rid18">18</a>]. This in vitro finding is compatible with the clinical observation that some patients with tumor-induced SIADH show evidence of osmoregulation of ADH release [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>Certain drugs can enhance ADH release or effect, including chlorpropamide, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> (a derivative of carbamazepine), high-dose intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and selective serotonin reuptake inhibitors (<a class="graphic graphic_table graphicRef118898" href="/d/graphic/118898.html" rel="external">table 1</a>) [<a href="#rid1">1,19-27</a>]. Experimental studies suggest that chlorpropamide may increase concentrating ability both by increasing sodium chloride reabsorption in the loop of Henle (thereby enhancing the efficiency of countercurrent exchange) and by augmenting collecting tubule permeability to water [<a href="#rid20">20</a>]. The latter effect may be mediated by an increased number of ADH receptors in the collecting tubule cells. Carbamazepine and oxcarbazepine also act at least in part by increasing the sensitivity to ADH [<a href="#rid21">21,22,25</a>].</p><p>SIADH due to high-dose intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> may be a particular problem since patients receiving this regimen are often fluid loaded to prevent hemorrhagic cystitis [<a href="#rid26">26,27</a>]. As a result, marked water retention and potentially fatal hyponatremia may ensue in selected cases [<a href="#rid26">26</a>]. This complication has been primarily described with doses in the range of 30 to 50 mg/kg used to treat malignancy, or 6 g/m<sup>2</sup> as given in the STAMP protocol in preparation for bone marrow rescue [<a href="#rid27">27</a>]. Although less common, hyponatremia can also occur with the lower doses (10 to 15 mg/kg) that are given as pulse therapy in autoimmune diseases such as lupus nephritis. Chemotherapy-induced nausea may play a contributory role since nausea is a potent stimulus to ADH release [<a href="#rid28">28</a>]. The fall in the plasma sodium concentration in this setting can be minimized by using isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> rather than free water to maintain a high urine output.</p><p>SIADH is also associated with the selective serotonin reuptake inhibitors (eg, <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>) [<a href="#rid29">29-33</a>]. The exact prevalence is unknown; patients above age 65 years may be more susceptible to the complication [<a href="#rid33">33</a>]. The risk of developing severe hyponatremia requiring hospitalization is greatest in the first few weeks after initiating treatment with these agents [<a href="#rid34">34</a>].</p><p>Many other drugs have been associated with the SIADH. These include <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9993" href="/d/drug information/9993.html" rel="external">thiothixene</a>, <a class="drug drug_general" data-topicid="9991" href="/d/drug information/9991.html" rel="external">thioridazine</a>, <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, monoamine oxidase inhibitors, <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, opiates, nonsteroidal antiinflammatory agents, interferon-alpha, interferon-gamma, sodium <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a>, lorcainide, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, high-dose <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, and "ecstasy" (methylenedioxymethamphetamine), a drug of abuse that may also be associated with excessive water intake [<a href="#rid1">1,29,35-39</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgical procedures are often associated with hypersecretion of ADH, a response that is probably mediated by pain afferents [<a href="#rid40">40-42</a>]. In addition, hyponatremia may develop after other types of interventional procedures, such as cardiac catheterization [<a href="#rid43">43</a>].</p><p>Hyponatremia is also a common late complication of <strong>transsphenoidal</strong> pituitary surgery, occurring in 21 to 35 percent of cases [<a href="#rid44">44,45</a>]. Although relative cortisol deficiency may contribute, the major cause is inappropriate ADH release from the injured posterior pituitary gland. The fall in the plasma sodium concentration is most severe on the sixth to seventh postoperative day. This form of isolated hyponatremia (or isolated second phase) appears to be a subset of the classic <strong>triphasic</strong> cycle in which initial polyuria is followed by transient SIADH and then either recovery or, in severe cases, a third phase of permanent central diabetes insipidus. (See  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p>Rarely, hyponatremia after pituitary surgery is due to cerebral salt wasting. (See <a class="local">'Cerebral salt wasting'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h2">Pulmonary disease</span><span class="headingEndMark"> — </span>Pulmonary diseases, particularly pneumonia (viral, bacterial, tuberculous), can lead to the SIADH, although the mechanism by which this occurs is not clear [<a href="#rid41">41</a>]. A similar response may infrequently be seen with asthma, atelectasis, acute respiratory failure, and pneumothorax [<a href="#rid1">1,41</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Hormone deficiency</span><span class="headingEndMark"> — </span>Both hypopituitarism and hypothyroidism may be associated with hyponatremia and an SIADH picture that can be corrected by hormone replacement. (See  <a class="medical medical_review" href="/d/html/2314.html" rel="external">"Hyponatremia and hyperkalemia in adrenal insufficiency"</a> and  <a class="medical medical_review" href="/d/html/2374.html" rel="external">"Causes of hypotonic hyponatremia in adults", section on 'Hypothyroidism'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Hormone administration</span><span class="headingEndMark"> — </span>The SIADH can by induced by exogenous hormone administration, as with vasopressin (to control gastrointestinal bleeding), <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (dDAVP; to treat von Willebrand disease or hemophilia or platelet dysfunction), or <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> (to induce labor) [<a href="#rid46">46-49</a>]. As with vasopressin and desmopressin, oxytocin acts by increasing the activity of the vasopressin-2 (V2; antidiuretic) receptor [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H16"><span class="h2">HIV infection</span><span class="headingEndMark"> — </span>A common cause of hyponatremia is symptomatic HIV infection, either the acquired immune deficiency syndrome (AIDS) or early symptomatic HIV infection [<a href="#rid51">51</a>]. Although volume depletion (due, for example, to gastrointestinal losses) or adrenal insufficiency may be responsible, many patients have the SIADH. Pneumonia, due to Pneumocystis carinii or other organisms, central nervous system infections, and malignant disease, are most often responsible in this setting [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/2375.html" rel="external">"Electrolyte disturbances with HIV infection"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Hereditary SIADH</span><span class="headingEndMark"> — </span>The clinical picture of SIADH may result from genetic disorders that result in antidiuresis. A mutation affecting the gene for the renal V2 receptor, which some investigators have named nephrogenic syndrome of inappropriate antidiuresis, has been found to cause clinically significant hyponatremia.</p><p>In the initial description of the nephrogenic syndrome, two male infants were described who presented with hyponatremia, hypoosmolality, increased urine osmolality, and a high urine sodium concentration consistent with SIADH, but with no detectable circulating ADH [<a href="#rid52">52,53</a>]. Gain-of-function mutations were found in the gene encoding the V2 receptor that mediates the antidiuretic response to ADH; persistent activation of the receptor was responsible for the persistent antidiuretic state [<a href="#rid54">54</a>]. The gene for the V2 receptor is located on the X chromosome, and loss-of-function mutations of the gene are responsible for X-linked nephrogenic diabetes insipidus. (See  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes", section on 'Hereditary AVP-R'</a>.)</p><p>The nephrogenic syndrome of inappropriate antidiuresis has also been found in adult men and women. In one study, a 74-year-old man with an initial diagnosis of SIADH was unresponsive to oral inhibitors of the V2 receptor; he was subsequently discovered to have a gain-of-function mutation of the gene for this receptor [<a href="#rid55">55</a>]. After screening of family members, two additional hemizygous males and four heterozygous females were identified. Spontaneous episodes of hyponatremia and/or an abnormal water load test were observed in all but one woman with the genetic defect, who had preferential inactivation of the X chromosome harboring the mutated allele.</p><p>Most patients with the nephrogenic syndrome of inappropriate antidiuresis harbor a mutation that "locks" the V2 receptor in the open position and thereby makes it unresponsive to vasopressin antagonists [<a href="#rid56">56</a>]. Gain-of-function mutations involving other regions of the gene have been reported in which response to vasopressin antagonists is preserved [<a href="#rid57">57</a>].</p><p>An activating mutation affecting the signaling pathway between the V2 receptor and cyclic adenosine monophosphate has been identified as another cause of the nephrogenic syndrome of antidiuresis in children with hyponatremia [<a href="#rid58">58</a>]. The mutation is located in the gene encoding the guanine-nucleotide alpha subunit (<em>GNAS</em>), which is involved in transmitting signals via the G protein-coupled V2 receptor.</p><p>Polymorphisms in the genes encoding the hypothalamic osmoreceptor, transient receptor potential vanilloid type 4 (TRPV4), may also cause mild hyponatremia [<a href="#rid59">59</a>]. Population studies show that men but, for reasons unknown, not women with a proline to serine substitution at residue 19 are two to six times more likely to have a serum sodium ≤135 mEq/L than men with the wild-type allele [<a href="#rid59">59</a>]. The mean serum sodium concentrations among men with one copy of the variant allele are lower by approximately 2 mEq/L. In vitro, TRPV4 channels with the variant allele are hyporesponsive to mild hypotonic stress but respond normally to severe osmotic stress. Thus, affected individuals would be expected to behave as if they have a reset osmostat, with a lower-than-normal serum sodium concentration that regulates normally around that value. Based upon what has been observed in genetically engineered mice that lack a functioning TRVPV4 channel, it has been postulated that humans with the variant hypofunctioning allele would exhibit unrestricted drinking, and therefore, more severe hyponatremia, if they were to develop SIADH for another reason. (See  <a class="medical medical_review" href="/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat", section on 'Reset osmostat'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Idiopathic</span><span class="headingEndMark"> — </span>Idiopathic SIADH has been described primarily in older adult patients [<a href="#rid60">60-63</a>]. However, some cases of apparently idiopathic disease were later found to be caused by an occult tumor (most often small cell carcinoma or olfactory neuroblastoma) and, in older patients, giant cell (temporal) arteritis [<a href="#rid1">1,61,64,65</a>].</p><p class="headingAnchor" id="H19"><span class="h1">CEREBRAL SALT WASTING</span><span class="headingEndMark"> — </span>A rare syndrome has been described in patients with cerebral disease (particularly subarachnoid hemorrhage) that mimics all of the findings in the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) except that salt wasting is thought to be the primary defect, with the ensuing volume depletion causing a secondary rise in antidiuretic hormone (ADH) release. This distinction is not easy to make since the true volume status of the patient is often difficult to ascertain. The pathogenesis, manifestations, and treatment of cerebral salt wasting are discussed separately. (See  <a class="medical medical_review" href="/d/html/2367.html" rel="external">"Cerebral salt wasting"</a>.)</p><p class="headingAnchor" id="H780230151"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109682.html" rel="external">"Society guideline links: Hyponatremia"</a>.)</p><p class="headingAnchor" id="H981068896"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86640.html" rel="external">"Patient education: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3609886"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a disorder of impaired water excretion caused by the inability to suppress the secretion of antidiuretic hormone (ADH). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">SIADH should be suspected in any patient with hyponatremia, hypoosmolality, and a urine osmolality above 100 mosmol/kg (<a class="graphic graphic_algorithm graphicRef101823" href="/d/graphic/101823.html" rel="external">algorithm 1</a>). In SIADH, the urine sodium concentration is usually above 40 mEq/L, the serum potassium concentration is normal, there is no acid-base disturbance, and the serum uric acid concentration is frequently low. (See <a class="local">'Introduction'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120063">(Related Pathway(s):  <a class="utd-content-120063" href="/pathway/120063?topicRef=2384&amp;source=see_link">Hyponatremia: Evaluation in adults</a>.)</span></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – ADH secretion results in a concentrated urine and therefore a reduced urine volume. In most patients with SIADH, ingestion of water does not adequately suppress ADH, and the urine remains concentrated. This leads to water retention, which increases total body water (TBW). This increase in TBW lowers the plasma sodium concentration by dilution. In addition, the increase in TBW transiently expands the extracellular fluid volume and thereby triggers increased urinary sodium excretion, which both returns the extracellular fluid volume toward normal and further lowers the plasma sodium concentration. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – One of the following causes of persistent ADH release is likely to be present in patients who fulfill the clinical criteria for the SIADH (see <a class="local">'Etiology'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any CNS disorder, including stroke, hemorrhage, infection, trauma, and psychosis can enhance ADH release. There is uncertainty as to whether hyponatremia in patients with severe neurologic disorders (such as hemorrhage or trauma) is due to SIADH or salt wasting (ie, cerebral salt wasting). (See <a class="local">'CNS disturbances'</a> above and <a class="local">'Cerebral salt wasting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ectopic production of ADH by a tumor is most often due to a small cell carcinoma of the lung and is rarely seen with other lung tumors. Less common causes of malignancy-associated SIADH include head and neck cancer, olfactory neuroblastoma (esthesioneuroblastoma), and extrapulmonary small cell carcinomas. (See <a class="local">'Malignancies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Certain drugs can enhance ADH release or effect, including chlorpropamide, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> (a derivative of carbamazepine), high-dose intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and selective serotonin reuptake inhibitors (<a class="graphic graphic_table graphicRef118898" href="/d/graphic/118898.html" rel="external">table 1</a>). Many other drugs have been associated with the SIADH. These include <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9993" href="/d/drug information/9993.html" rel="external">thiothixene</a>, <a class="drug drug_general" data-topicid="9991" href="/d/drug information/9991.html" rel="external">thioridazine</a>, <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, monoamine oxidase inhibitors, <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, opiates, nonsteroidal antiinflammatory agents, interferon-alpha, interferon-gamma, sodium <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a>, lorcainide, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, and high-dose <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>. "Ecstasy" (methylenedioxymethamphetamine) is a drug of abuse that may also be associated with both SIADH and excessive water intake. (See <a class="local">'Drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical procedures are often associated with hypersecretion of ADH, a response that is probably mediated by pain afferents. In addition, hyponatremia may develop after other interventional medical procedures, such as cardiac catheterization. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary diseases, particularly pneumonia (viral, bacterial, tuberculous), can lead to the SIADH, although the mechanism by which this occurs is not clear. A similar response may infrequently be seen with asthma, atelectasis, acute respiratory failure, and pneumothorax. (See <a class="local">'Pulmonary disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Both hypopituitarism and hypothyroidism may be associated with hyponatremia and clinical findings identical to SIADH, but these abnormalities are corrected by hormone replacement. (See <a class="local">'Hormone deficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SIADH can by induced by exogenous administration of hormones: vasopressin (to control gastrointestinal bleeding); ADH analogs, such as <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (dDAVP; to treat von Willebrand disease, hemophilia, other forms of platelet dysfunction, or enuresis); or other hormones with antidiuretic effects, such as <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> (to induce labor). (See <a class="local">'Hormone administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic HIV infection is associated with SIADH. (See <a class="local">'HIV infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The clinical picture of SIADH may result from genetic disorders that result in antidiuresis. (See <a class="local">'Hereditary SIADH'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.703.</li><li><a class="nounderline abstract_t">Steele A, Gowrishankar M, Abrahamson S, et al. Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination. Ann Intern Med 1997; 126:20.</a></li><li><a class="nounderline abstract_t">Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 2006; 119:S36.</a></li><li><a class="nounderline abstract_t">Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976; 10:25.</a></li><li><a class="nounderline abstract_t">Fenske WK, Christ-Crain M, Hörning A, et al. A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis. J Am Soc Nephrol 2014; 25:2376.</a></li><li><a class="nounderline abstract_t">Verbalis JG, Drutarosky MD. Adaptation to chronic hypoosmolality in rats. Kidney Int 1988; 34:351.</a></li><li><a class="nounderline abstract_t">Gross PA, Anderson RJ. Effects of DDAVP and AVP on sodium and water balance in conscious rat. Am J Physiol 1982; 243:R512.</a></li><li><a class="nounderline abstract_t">LEAF A, BARTTER FC, SANTOS RF, WRONG O. Evidence in man that urinary electrolyte loss induced by pitressin is a function of water retention. J Clin Invest 1953; 32:868.</a></li><li><a class="nounderline abstract_t">JAENIKE JR, WATERHOUSE C. The renal response to sustained administration of vasopressin and water in man. J Clin Endocrinol Metab 1961; 21:231.</a></li><li><a class="nounderline abstract_t">Ecelbarger CA, Nielsen S, Olson BR, et al. Role of renal aquaporins in escape from vasopressin-induced antidiuresis in rat. J Clin Invest 1997; 99:1852.</a></li><li><a class="nounderline abstract_t">Murase T, Ecelbarger CA, Baker EA, et al. Kidney aquaporin-2 expression during escape from antidiuresis is not related to plasma or tissue osmolality. J Am Soc Nephrol 1999; 10:2067.</a></li><li><a class="nounderline abstract_t">Saito T, Higashiyama M, Nagasaka S, et al. Role of aquaporin-2 gene expression in hyponatremic rats with chronic vasopressin-induced antidiuresis. Kidney Int 2001; 60:1266.</a></li><li><a class="nounderline abstract_t">Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064.</a></li><li><a class="nounderline abstract_t">Johnson BE, Chute JP, Rushin J, et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 1997; 156:1669.</a></li><li><a class="nounderline abstract_t">Ferlito A, Rinaldo A, Devaney KO. Syndrome of inappropriate antidiuretic hormone secretion associated with head neck cancers: review of the literature. Ann Otol Rhinol Laryngol 1997; 106:878.</a></li><li><a class="nounderline abstract_t">Talmi YP, Wolf GT, Hoffman HT, Krause CJ. Elevated arginine vasopressin levels in squamous cell cancer of the head and neck. Laryngoscope 1996; 106:317.</a></li><li><a class="nounderline abstract_t">Sørensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995; 238:97.</a></li><li><a class="nounderline abstract_t">Kim JK, Summer SN, Wood WM, Schrier RW. Osmotic and non-osmotic regulation of arginine vasopressin (AVP) release, mRNA, and promoter activity in small cell lung carcinoma (SCLC) cells. Mol Cell Endocrinol 1996; 123:179.</a></li><li><a class="nounderline abstract_t">Weissman PN, Shenkman L, Gregerman RI. Chlorpropamide hyponatremia: drug-induced inappropriate antidiuretic-hormone activity. N Engl J Med 1971; 284:65.</a></li><li><a class="nounderline abstract_t">Hensen J, Haenelt M, Gross P. Water retention after oral chlorpropamide is associated with an increase in renal papillary arginine vasopressin receptors. Eur J Endocrinol 1995; 132:459.</a></li><li><a class="nounderline abstract_t">Gold PW, Robertson GL, Ballenger JC, et al. Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation. J Clin Endocrinol Metab 1983; 57:952.</a></li><li><a class="nounderline abstract_t">Kamiyama T, Iseki K, Kawazoe N, et al. Carbamazepine-induced hyponatremia in a patient with partial central diabetes insipidus. Nephron 1993; 64:142.</a></li><li><a class="nounderline abstract_t">Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35:181.</a></li><li><a class="nounderline abstract_t">Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res 1988; 2:269.</a></li><li><a class="nounderline abstract_t">Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 2002; 51:613.</a></li><li><a class="nounderline abstract_t">Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985; 145:548.</a></li><li><a class="nounderline abstract_t">Salido M, Macarron P, Hernández-García C, et al. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus. Lupus 2003; 12:636.</a></li><li><a class="nounderline abstract_t">Nausea and vasopressin. Lancet 1991; 337:1133.</a></li><li><a class="nounderline abstract_t">ten Holt WL, van Iperen CE, Schrijver G, Bartelink AK. Severe hyponatremia during therapy with fluoxetine. Arch Intern Med 1996; 156:681.</a></li><li><a class="nounderline abstract_t">Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 1996; 155:519.</a></li><li><a class="nounderline abstract_t">Covyeou JA, Jackson CW. Hyponatremia associated with escitalopram. N Engl J Med 2007; 356:94.</a></li><li><a class="nounderline abstract_t">Ozturk S, Ozsenel EB, Kazancioglu R, Turkmen A. A case of fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion. Nat Clin Pract Nephrol 2008; 4:278.</a></li><li><a class="nounderline abstract_t">Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med 2004; 164:327.</a></li><li><a class="nounderline abstract_t">Mannheimer B, Falhammar H, Calissendorff J, et al. Time-dependent association between selective serotonin reuptake inhibitors and hospitalization due to hyponatremia. J Psychopharmacol 2021; 35:928.</a></li><li><a class="nounderline abstract_t">Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA). Lancet 1996; 347:1052.</a></li><li><a class="nounderline abstract_t">Wilkins B. Cerebral oedema after MDMA ("ecstasy") and unrestricted water intake. Hyponatraemia must be treated with low water input. BMJ 1996; 313:689.</a></li><li><a class="nounderline abstract_t">Adler D, Voide C, Thorens JB, Desmeules J. SIADH consecutive to ciprofloxacin intake. Eur J Intern Med 2004; 15:463.</a></li><li><a class="nounderline abstract_t">Liapis K, Apostolidis J, Charitaki E, et al. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib. Ann Pharmacother 2008; 42:1882.</a></li><li><a class="nounderline abstract_t">Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis 2008; 52:144.</a></li><li><a class="nounderline abstract_t">Fieldman NR, Forsling ML, Le Quesne LP. The effect of vasopressin on solute and water excretion during and after surgical operations. Ann Surg 1985; 201:383.</a></li><li><a class="nounderline abstract_t">Anderson RJ. Hospital-associated hyponatremia. Kidney Int 1986; 29:1237.</a></li><li><a class="nounderline abstract_t">Gowrishankar M, Lin SH, Mallie JP, et al. Acute hyponatremia in the perioperative period: insights into its pathophysiology and recommendations for management. Clin Nephrol 1998; 50:352.</a></li><li><a class="nounderline abstract_t">Aronson D, Dragu RE, Nakhoul F, et al. Hyponatremia as a complication of cardiac catheterization: a prospective study. Am J Kidney Dis 2002; 40:940.</a></li><li><a class="nounderline abstract_t">Sane T, Rantakari K, Poranen A, et al. Hyponatremia after transsphenoidal surgery for pituitary tumors. J Clin Endocrinol Metab 1994; 79:1395.</a></li><li><a class="nounderline abstract_t">Olson BR, Rubino D, Gumowski J, Oldfield EH. Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab 1995; 80:85.</a></li><li><a class="nounderline abstract_t">Dunn AL, Powers JR, Ribeiro MJ, et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6:11.</a></li><li><a class="nounderline abstract_t">Shepherd LL, Hutchinson RJ, Worden EK, et al. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989; 114:470.</a></li><li><a class="nounderline abstract_t">Humphries JE, Siragy H. Significant hyponatremia following DDAVP administration in a healthy adult. Am J Hematol 1993; 44:12.</a></li><li><a class="nounderline abstract_t">Feeney JG. Water intoxication and oxytocin. Br Med J (Clin Res Ed) 1982; 285:243.</a></li><li><a class="nounderline abstract_t">Li C, Wang W, Summer SN, et al. Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol 2008; 19:225.</a></li><li><a class="nounderline abstract_t">Vitting KE, Gardenswartz MH, Zabetakis PM, et al. Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome. JAMA 1990; 263:973.</a></li><li><a class="nounderline abstract_t">Gitelman SE, Feldman BJ, Rosenthal SM. Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients. Am J Med 2006; 119:S54.</a></li><li><a class="nounderline abstract_t">Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005; 352:1884.</a></li><li><a class="nounderline abstract_t">Carpentier E, Greenbaum LA, Rochdi D, et al. Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD. J Am Soc Nephrol 2012; 23:1635.</a></li><li><a class="nounderline abstract_t">Decaux G, Vandergheynst F, Bouko Y, et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007; 18:606.</a></li><li><a class="nounderline abstract_t">Powlson AS, Challis BG, Halsall DJ, et al. Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2. Clin Endocrinol (Oxf) 2016; 85:306.</a></li><li><a class="nounderline abstract_t">Erdélyi LS, Mann WA, Morris-Rosendahl DJ, et al. Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis. Kidney Int 2015; 88:1070.</a></li><li><a class="nounderline abstract_t">Miyado M, Fukami M, Takada S, et al. Germline-Derived Gain-of-Function Variants of Gsα-Coding GNAS Gene Identified in Nephrogenic Syndrome of Inappropriate Antidiuresis. J Am Soc Nephrol 2019; 30:877.</a></li><li><a class="nounderline abstract_t">Tian W, Fu Y, Garcia-Elias A, et al. A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 gene is associated with human hyponatremia. Proc Natl Acad Sci U S A 2009; 106:14034.</a></li><li><a class="nounderline abstract_t">Goldstein CS, Braunstein S, Goldfarb S. Idiopathic syndrome of inappropriate antidiuretic hormone secretion possibly related to advanced age. Ann Intern Med 1983; 99:185.</a></li><li><a class="nounderline abstract_t">Sterns RH. The syndrome of inappropriate antidiuretic hormone secretion of unknown origin. Am J Kidney Dis 1999; 33:161.</a></li><li><a class="nounderline abstract_t">Miller M, Hecker MS, Friedlander DA, Carter JM. Apparent idiopathic hyponatremia in an ambulatory geriatric population. J Am Geriatr Soc 1996; 44:404.</a></li><li><a class="nounderline abstract_t">Anpalahan M. Chronic idiopathic hyponatremia in older people due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) possibly related to aging. J Am Geriatr Soc 2001; 49:788.</a></li><li><a class="nounderline abstract_t">Inappropriate antidiuretic hormone secretion of unknown origin. Kidney Int 1980; 17:554.</a></li><li><a class="nounderline abstract_t">Gentric A, Baccino E, Mottier D, et al. Temporal arteritis revealed by a syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1988; 85:559.</a></li></ol></div><div id="topicVersionRevision">Topic 2384 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.703.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8992919" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16843083" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/181630" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The osmoregulation of vasopressin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24722436" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3172643" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adaptation to chronic hypoosmolality in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7137381" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effects of DDAVP and AVP on sodium and water balance in conscious rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13084753" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evidence in man that urinary electrolyte loss induced by pitressin is a function of water retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13789146" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The renal response to sustained administration of vasopressin and water in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9109429" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Role of renal aquaporins in escape from vasopressin-induced antidiuresis in rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10505682" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Kidney aquaporin-2 expression during escape from antidiuresis is not related to plasma or tissue osmolality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576341" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Role of aquaporin-2 gene expression in hyponatremic rats with chronic vasopressin-induced antidiuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17507705" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical practice. The syndrome of inappropriate antidiuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9372692" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A prospective study of patients with lung cancer and hyponatremia of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9342988" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Syndrome of inappropriate antidiuretic hormone secretion associated with head neck cancers: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8614196" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Elevated arginine vasopressin levels in squamous cell cancer of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629492" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961255" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Osmotic and non-osmotic regulation of arginine vasopressin (AVP) release, mRNA, and promoter activity in small cell lung carcinoma (SCLC) cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5538636" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chlorpropamide hyponatremia: drug-induced inappropriate antidiuretic-hormone activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7711884" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Water retention after oral chlorpropamide is associated with an increase in renal papillary arginine vasopressin receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6619270" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8502320" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Carbamazepine-induced hyponatremia in a patient with partial central diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8112243" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3197696" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Oxcarbazepine-induced hyponatremia, a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12112108" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of oxcarbazepine on sodium concentration and water handling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3977522" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Water intoxication following moderate-dose intravenous cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12945725" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1674020" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nausea and vasopressin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629882" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Severe hyponatremia during therapy with fluoxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804257" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202465" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hyponatremia associated with escitalopram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18317501" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A case of fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769630" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Paroxetine-induced hyponatremia in older adults: a 12-week prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33860708" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Time-dependent association between selective serotonin reuptake inhibitors and hospitalization due to hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606600" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8811776" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cerebral oedema after MDMA ("ecstasy") and unrestricted water intake. Hyponatraemia must be treated with low water input.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15581752" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : SIADH consecutive to ciprofloxacin intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017824" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18468754" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A review of drug-induced hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3977441" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effect of vasopressin on solute and water excretion during and after surgical operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3747337" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hospital-associated hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9877108" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acute hyponatremia in the perioperative period: insights into its pathophysiology and recommendations for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12407638" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hyponatremia as a complication of cardiac catheterization: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962334" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hyponatremia after transsphenoidal surgery for pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829644" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Isolated hyponatremia after transsphenoidal pituitary surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632735" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2921692" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8342559" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Significant hyponatremia following DDAVP administration in a healthy adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6807433" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Water intoxication and oxytocin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057218" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Molecular mechanisms of antidiuretic effect of oxytocin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2299765" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16843086" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872203" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nephrogenic syndrome of inappropriate antidiuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22956819" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229917" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26715131" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26131744" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30962325" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Germline-Derived Gain-of-Function Variants of Gsα-Coding GNAS Gene Identified in Nephrogenic Syndrome of Inappropriate Antidiuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19666518" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 gene is associated with human hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6881773" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Idiopathic syndrome of inappropriate antidiuretic hormone secretion possibly related to advanced age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9915284" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The syndrome of inappropriate antidiuretic hormone secretion of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636585" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Apparent idiopathic hyponatremia in an ambulatory geriatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454119" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Chronic idiopathic hyponatremia in older people due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) possibly related to aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6771455" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Inappropriate antidiuretic hormone secretion of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177406" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Temporal arteritis revealed by a syndrome of inappropriate secretion of antidiuretic hormone.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
